Brokers Offer Predictions for KalVista Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for KalVista Pharmaceuticals in a research report issued on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz forecasts that the specialty pharmaceutical company will post earnings of ($0.72) per share for the quarter. The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals' Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.70) EPS and FY2025 earnings at ($2.83) EPS.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its quarterly earnings data on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.09).

Several other analysts also recently commented on KALV. HC Wainwright boosted their target price on shares of KalVista Pharmaceuticals from $16.00 to $24.00 and gave the stock a "buy" rating in a research report on Wednesday, February 14th. Needham & Company LLC reaffirmed a "buy" rating and set a $35.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday, April 11th.

KalVista Pharmaceuticals Stock Down 1.3 %

KALV stock traded down $0.15 during trading hours on Thursday, hitting $11.50. The company's stock had a trading volume of 408,653 shares, compared to its average volume of 751,119. The company has a market capitalization of $485.19 million, a PE ratio of -3.71 and a beta of 0.88. KalVista Pharmaceuticals has a 12 month low of $7.21 and a 12 month high of $16.88. The stock has a 50 day moving average price of $12.85 and a two-hundred day moving average price of $11.24.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 4,174 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, January 26th. The shares were bought at an average price of $12.98 per share, with a total value of $54,178.52. Following the purchase, the insider now owns 4,569,984 shares of the company's stock, valued at $59,318,392.32. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, major shareholder Venrock Healthcare Capital Par bought 4,174 shares of the company's stock in a transaction on Friday, January 26th. The shares were purchased at an average cost of $12.98 per share, for a total transaction of $54,178.52. Following the acquisition, the insider now owns 4,569,984 shares of the company's stock, valued at approximately $59,318,392.32. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CFO Benjamin L. Palleiko sold 22,802 shares of the firm's stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $14.11, for a total transaction of $321,736.22. Following the sale, the chief financial officer now owns 187,315 shares in the company, valued at $2,643,014.65. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 207,227 shares of company stock valued at $2,808,574 and have sold 75,978 shares valued at $1,070,918. Insiders own 12.30% of the company's stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its position in shares of KalVista Pharmaceuticals by 24.9% in the first quarter. JPMorgan Chase & Co. now owns 13,424 shares of the specialty pharmaceutical company's stock valued at $198,000 after acquiring an additional 2,677 shares during the period. Bank of New York Mellon Corp raised its stake in KalVista Pharmaceuticals by 5.8% during the first quarter. Bank of New York Mellon Corp now owns 69,570 shares of the specialty pharmaceutical company's stock worth $1,026,000 after acquiring an additional 3,838 shares in the last quarter. MetLife Investment Management LLC raised its stake in KalVista Pharmaceuticals by 103.8% during the first quarter. MetLife Investment Management LLC now owns 12,495 shares of the specialty pharmaceutical company's stock worth $184,000 after acquiring an additional 6,365 shares in the last quarter. Rhumbline Advisers raised its stake in KalVista Pharmaceuticals by 16.3% during the first quarter. Rhumbline Advisers now owns 22,150 shares of the specialty pharmaceutical company's stock worth $326,000 after acquiring an additional 3,100 shares in the last quarter. Finally, BlackRock Inc. raised its stake in KalVista Pharmaceuticals by 2.6% during the first quarter. BlackRock Inc. now owns 1,544,027 shares of the specialty pharmaceutical company's stock worth $22,757,000 after acquiring an additional 39,407 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.